4.8 Article

Quantification of circulating HBV RNA expressed from intrahepatic cccDNA in untreated and NUC treated patients with chronic hepatitis B

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Article Gastroenterology & Hepatology

Quantification of the hepatitis B virus cccDNA: evidence-based guidelines for monitoring the key obstacle of HBV cure

Lena Allweiss et al.

Summary: A major goal of hepatitis B virus (HBV) treatments is to reduce or inactivate intrahepatic viral covalently closed circular DNA (cccDNA). There are different methods for cccDNA quantification, such as Southern blot (SB) and quantitative PCR (qPCR). This study compared various protocols for cccDNA isolation and qPCR quantification in liver tissues and cell cultures, aiming to develop evidence-based guidance for best practices.
Editorial Material Gastroenterology & Hepatology

Hepatitis B RNA and Core-Related Antigen Provide Value Beyond DNA in Evaluating e But Not Surface Antigen Clearance

Wendy C. King et al.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2023)

Article Gastroenterology & Hepatology

Intrahepatic quantification of HBV antigens in chronic hepatitis B reveals heterogeneity and treatment-mediated reductions in HBV core-positive cells

Abhishek Aggarwal et al.

Summary: This study quantified the patterns of HBV antigen expression in liver biopsies from individuals with chronic hepatitis B using a novel four-plex immunofluorescence assay and image analysis. The findings revealed variations in HBV staining within individuals and the effects of disease stage and NUC treatment. Correlations between liver and peripheral viral biomarkers were observed, particularly in samples from HBeAg-positive individuals.

JHEP REPORTS (2023)

Article Gastroenterology & Hepatology

Early intrahepatic recurrence of HBV infection in liver transplant recipients despite antiviral prophylaxis

Francois Vileret et al.

Summary: This study found that viral recurrence can occur rapidly after liver transplantation, despite prophylaxis with nucleos(t)ide analogues (NUCs) and hepatitis B immunoglobulin (HBIG). The majority of patients had at least one HBV marker detected in either serum or the liver 12 months after transplantation. Optimal patient compliance to antiviral prophylaxis is crucial to prevent viral rebound.

JHEP REPORTS (2023)

Article Gastroenterology & Hepatology

Evaluation of the HBV liver reservoir with fine needle aspirates

Barbara Testoni et al.

Summary: This study validated the possibility to quantify cccDNA and assess its transcriptional activity in patients with chronic hepatitis B by combining FNA and droplet digital PCR. The use of FNA in clinical trials to evaluate the intrahepatic viral reservoir during the development of new antivirals and immunomodulatory agents is supported.

JHEP REPORTS (2023)

Article Virology

Performance of the cobas® HBV RNA automated investigational assay for the detection and quantification of circulating HBV RNA in chronic HBV patients

Caroline Scholtes et al.

Summary: This study evaluated the performance of an HBV RNA assay on the cobas(R) 6800/8800 systems and found that it is a high throughput, sensitive, and inclusive assay for monitoring antiviral treatment in patients with chronic hepatitis B.

JOURNAL OF CLINICAL VIROLOGY (2022)

Article Immunology

Hepatitis B Virus RNA as Early Predictor for Response to Pegylated Interferon Alpha in HBeAg-Negative Chronic Hepatitis B

Mina S. Farag et al.

Summary: During PEG-IFN treatment for HBeAg-negative CHB, HBV-RNA showed a rapid and significant decrease that correlated with treatment response and HBsAg loss at long-term follow-up.

CLINICAL INFECTIOUS DISEASES (2021)

Article Virology

Serum HBV RNA correlated with intrahepatic cccDNA more strongly than other HBV markers during peg-interferon treatment

Xiaomei Wang et al.

Summary: In HBeAg-positive patients, serum HBV RNA showed a stronger correlation with cccDNA levels compared to other HBV markers, especially in patients with HBeAg seroconversion.

VIROLOGY JOURNAL (2021)

Article Pharmacology & Pharmacy

Methodology-dependent performance of serum HBV RNA in predicting treatment outcomes in chronic hepatitis B patients

Shi Liu et al.

Summary: The performance of serum HBV RNA detection in predicting treatment outcomes in patients with chronic hepatitis B is methodology-dependent, and detection of PolyA-RNA is not recommended for predicting off-treatment relapses.

ANTIVIRAL RESEARCH (2021)

Article Gastroenterology & Hepatology

Ubiquitous expression of HBsAg from integrated HBV DNA in patients with low viral load

Marie-Anne Meier et al.

Summary: Integrated HBV DNA can contribute to HBsAg production independently of viral replication, and transcribed HBV integration can extend to the entire liver in some HBe-negative patients, leading to ubiquitous HBsAg expression. This questions the clinical utility of HBsAg as a surrogate marker for viral replication in patients with low serum viral loads.

JOURNAL OF HEPATOLOGY (2021)

Article Gastroenterology & Hepatology

Clinical efficacy of a novel, high-sensitivity HBcrAg assay in the management of chronic hepatitis B and HBV reactivation

Takako Inoue et al.

Summary: A fully automated, novel high-sensitivity hepatitis B core-related antigen assay (iTACT-HBcrAg) has been developed for monitoring chronic hepatitis B (CHB) and for the early detection of HBV reactivation. The clinical performance of iTACT-HBcrAg was compared with other HBV markers, showing satisfactory analytical performance and potential as a general marker of disease progression and treatment response.

JOURNAL OF HEPATOLOGY (2021)

Review Gastroenterology & Hepatology

Covalently closed circular DNA: The ultimate therapeutic target for curing HBV infections

Maria Guadalupe Martinez et al.

Summary: Current antiviral therapies for chronic hepatitis B can improve patients' quality of life but do not cure infected hepatocytes. Complete HBV cure requires therapies targeting the cccDNA pool directly. New technologies aim to achieve non-cytolytic direct cccDNA targeting for cure.

JOURNAL OF HEPATOLOGY (2021)

Review Virology

Novel Biomarkers of Hepatitis B Virus and Their Use in Chronic Hepatitis B Patient Management

Alicia Vachon et al.

Summary: Despite the lack of predictive markers for guiding clinical management and allowing treatment cessation with reduced risk of viral reactivation, the development of novel HBV biomarkers is helping to improve the management of individuals with chronic hepatitis B. The utility of these biomarkers in both treatment-naive and treated CHB patients has been widely discussed.

VIRUSES-BASEL (2021)

Review Pharmacology & Pharmacy

Hepatitis B virus biology and life cycle

Senko Tsukuda et al.

ANTIVIRAL RESEARCH (2020)

Article Microbiology

Biogenesis and molecular characteristics of serum hepatitis B virus RNA

Sheng Shen et al.

PLOS PATHOGENS (2020)

Article Medicine, Research & Experimental

Single hepatocytes show persistence and transcriptional inactivity of hepatitis B

Ashwin Balagopal et al.

JCI INSIGHT (2020)

Review Pharmacology & Pharmacy

Non-invasive biomarkers for chronic hepatitis B virus infection management

Caroline Charre et al.

ANTIVIRAL RESEARCH (2019)

Review Biotechnology & Applied Microbiology

Therapeutic strategies for hepatitis B virus infection: towards a cure

Gregory C. Fanning et al.

NATURE REVIEWS DRUG DISCOVERY (2019)

Article Gastroenterology & Hepatology

Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance

Norah A. Terrault et al.

HEPATOLOGY (2018)

Letter Gastroenterology & Hepatology

Serum HBV pgRNA as a clinical marker for cccDNA activity

Katja Giersch et al.

JOURNAL OF HEPATOLOGY (2017)